Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data

Kohl, Katrin; Walop, Wikke; Gidudu, Jane; Ball, Leslie D.; Halperin, Scott A.; Hammer, Sandra Jo; Heath, Paul T; Varricchio, Frederick; Rothstein, Edward; Schuind, Anne; Hennig, Renald

doi:10.1016/j.vaccine.2007.04.056

Cited by 37 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brighton collaboration guidelines were used for analysis of redness, swelling and fever. 27,28 Pre-booster and post-booster follow up. Infants who were a part of per-protocol population (PPP); completed primary series of immunization and reported for a booster dose during 15-24 months, were followed up further to evaluate the booster dose immunogenicity and safety.…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

Sharma¹,

Yadav²,

Lalwani³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

Sharma¹,

Yadav²,

Lalwani³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

“…Reaksi lokal yang ditimbulkan sangat mungkin berhubungan dengan komponen pertusis pada vaksin DTP. 11 Apabila dibanding dengan uji klinis fase III, reaksi lokal yang ditemukan pada studi ini umumnya lebih tinggi. Hal ini dapat disebabkan oleh perbedaan petugas yang melakukan pengamatan.…”

Section: 11unclassified

Profil Keamanan setelah Pemberian Dosis Primer Vaksin Pentabio® pada Bayi di Indonesia

Sundoro¹,

Rusmil²,

Sitaresmi³

et al. 2017

mkb

View full text Add to dashboard Cite

“…These local reactions are of minor importance in the general population and typically do not interfere relevantly with business requirements [22–25]. However, this is not necessarily true in athletes.…”

Section: Principles Of Vaccination In Elite Athletesmentioning

confidence: 99%

Vaccination in Elite Athletes

Гартнер

Meyer

2014

Sports Med

View full text Add to dashboard Cite

Public health vaccination guidelines cannot be easily transferred to elite athletes. An enhanced benefit from preventing even mild diseases is obvious but stronger interference from otherwise minor side effects has to be considered as well. Thus, special vaccination guidelines for adult elite athletes are required. In most of them, protection should be strived for against tetanus, diphtheria, pertussis, influenza, hepatitis A, hepatitis B, measles, mumps and varicella. When living or traveling to endemic areas, the athletes should be immune against tick-borne encephalitis, yellow fever, Japanese encephalitis, poliomyelitis, typhoid fever, and meningococcal disease. Vaccination against pneumococci and Haemophilus influenzae type b is only relevant in athletes with certain underlying disorders. Rubella and papillomavirus vaccination might be considered after an individual risk–benefit analysis. Other vaccinations such as cholera, rabies, herpes zoster, and Bacille Calmette–Guérin (BCG) cannot be universally recommended for athletes at present. Only for a very few diseases, a determination of antibody titers is reasonable to avoid unnecessary vaccinations or to control efficacy of an individual’s vaccination (especially for measles, mumps, rubella, varicella, hepatitis B and, partly, hepatitis A). Vaccinations should be scheduled in a way that possible side effects are least likely to occur in periods of competition. Typically, vaccinations are well tolerated by elite athletes, and resulting antibody titers are not different from the general population. Side effects might be reduced by an optimal selection of vaccines and an appropriate technique of administration. Very few discipline-specific considerations apply to an athlete’s vaccination schedule mainly from the competition and training pattern as well as from the typical geographical distribution of competitive sites.

show abstract

Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data

Cited by 37 publications

References 17 publications

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

Profil Keamanan setelah Pemberian Dosis Primer Vaksin Pentabio® pada Bayi di Indonesia

Vaccination in Elite Athletes

Contact Info

Product

Resources

About